Tradestie Institutional Equity Comparison Engine

SGMO vs ACRS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGMO Overall Edge

SGMO Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sangamo Therapeutics, Inc. Common Stock (SGMO) driven by superior Valuation, Growth & Margin, Options & Structure while ACRS counters with relative strength in Momentum & Technical. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus ACRS at N/M Forward P/E and -1412.4% operating margin (-55.1% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against ACRS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
SGMO 0.4x vs ACRS N/M Fwd P/E
Growth & Margin Winner SGMO
Op Margin -175.5% vs -1412.4% ยท YoY +88.4% vs -55.1%
Momentum & Technical Winner ACRS
1Y -76.0% vs +55.0% ยท 52W Pos 9% vs 31%
Options & Structure Winner SGMO
UNCLASSIFIED (71st %ile IV) vs BREAKDOWN (1st %ile IV)
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.60
-8.29% 1D
Market Cap $620.2M
1M Return +9.6%
1Y Return +54.96%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 25.0 Fund 50.0 Flow 63.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGMO -76.04% ACRS +54.96% Spread: +155.72 pp (ACRS Lead)

Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SGMO Revenue ACRS Revenue SGMO Op. Margin ACRS Op. Margin Margin Edge
Q3 '25 $0M $10M -6119.3% -516.8% ACRS
Q4 '25 $60M $10M -175.5% -1724.6% SGMO
Q1 '26 $10M $10M -2215.4% -1111.8% ACRS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGMO (5) vs ACRS (4)
Institutional Metric SGMO ACRS Criterion Row Winner
Market Capitalization Scale $55.9M $620.2M Larger Scale ACRS
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY) Growth +88.4% -55.1% Higher Growth SGMO
Operating Margin (TTM) Profitability -175.5% -1412.4% Higher Margin SGMO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2891.8% -55.5% Higher ROE ACRS
52-Week Range Position Momentum 9% ($0โ€“$1) 31% ($2โ€“$7) Stronger Trend ACRS
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 206% Vol 1.54ฮฒ ยท 75% Vol Lower Realized Risk ACRS
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGMO vs ACRS Buy Guide
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
129d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live ACRS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGMO nor ACRS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.